

99/19 PH ASTA Medica AG

- 14 -

Pat nt claims:

Pharmaceutical preparation comprising, separately or together, an efficacious amount of (i) a soft steroid and/or a pharmaceutically tolerable ester thereof and (ii) at least one β_2 adrenoceptor agonist for simultaneous, sequential or separate administration by inhalation in the treatment of airway disorders in mammals.

10

5

Pharmaceutical preparation according to Claim 1, 2. that the soft steroid characterized in loteprednol or a pharmaceutically tolerable ester thereof.

15

20

3. Pharmaceutical preparation according to Claim 1 or 2, characterized in that the soft steroid is loteprednol etabonate.

Pharmaceutical preparation according to

Claims 1 to 3, characterized

4.

adrenoceptor agonist is selected from the group consisting of salbutamol, reproterol, salmeterol, formoterol and their pharmaceutically tolerable

one

the

in that

25 salts.

> Pharmaceutical preparation according to one of 5. Claims 1 to 4, characterized in that it contains (i) loteprednol and (ii) formoterol.

30

- Pharmaceutical preparation according to one of 6. Claims 1 to 4, characterized in that it contains (i) loteprednol and (ii) salmeterol.
- Pharmaceutical preparation according to one of 35 7. Claims 1 to 4, characterized in that it contains (i) loteprednol and (ii) reproterol.

5

- 8. Medicament for the treatment of allergies and/or airway disorders, comprising an efficacious amount of (i) loteprednol and (ii) at least one β_2 sympathomimetic in a fixed or free combination, if appropriate together with customary excipients or vehicles.
- 9. Process for the production of a medicament for the treatment of allergies and/or airway disorders, comprising the active compound loteprednol and at least one β_2 sympathomimetic, characterized in that loteprednol and the β_2 sympathomimetic or the β_2 sympathomimetics are mixed individually or together, if appropriate together with customary excipients or vehicles, and the mixture thus obtained is converted into suitable administration forms.
- 10. Use of the combination of loteprednol and at least one β_2 sympathomimetic for the production of a medicament for the simultaneous, sequential or separate treatment of allergies and/or airway disorders.